Evidence map›Paper›PMID 26484297›Full record

ArticleGenomics data2015

Deep sequencing of mRNA in CD24(-) and CD24(+) mammary carcinoma Mvt1 cell line.

Ran Rostoker, Anitha D Jayaprakash, Ravi Sachidanandam, Derek LeRoith

Open access · goldAbstract read
In one paragraph

Article in Genomics data, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ran RostokerDiabetes and Metabolism Clinical Research Center of Excellence, Clinical Research Institute at Rambam (CRIR), Haifa 31096, Israel ; Faculty of Medicine, Technion, Rambam Medical Center, Haifa 31096, Israel.
Anitha D JayaprakashGirihlet Inc., 423 West 127th Street, First Floor, NY 10027, United States.
Ravi SachidanandamDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, NY 10029, United States.
Derek LeRoithDepartments of Medicine, Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, NY 10029, United States.
Icahn School of Medicine at Mount Sinai · USTechnion – Israel Institute of Technology · IL

Funding

Mechanisms for the pro-metastatic effects of hyperinsulinemia on breast cancerR01CA128799 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEROITH, DEREK · 2008 to 2018
$3.7M
Rapid and inexpensive epi/genetic profiling of the human mitochondrial genomeR21HG007394 · NHGRI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SACHIDANANDAM, RAVI · 2013 to 2014
$465k
NCI NIH HHS R01 CA128799NHGRI NIH HHS R21 HG007394
6 · The paper itself

Abstract

CD24 is an anchored cell surface marker that is highly expressed in cancer cells (Lee et al., 2009) and its expression is associated with poorer outcome of cancer patients (Kristiansen et al., 2003). Phenotype comparison between two subpopulations derived from the Mvt1 cell line, CD24(-) cells (with no CD24 cell surface expression) and the CD24(+) cells, identified high tumorigenic capacity for the CD24(+) cells. In order to reveal the transcripts that support the CD24(+) aggressive and invasive phenotype we compared the gene profiles of these two subpopulations. mRNA profiles of CD24(-) and CD24(+) cells were generated by deep sequencing, in triplicate, using an Illumina HiSeq 2500. Here we provide a detailed description of the mRNA-seq analysis from our recent study (Rostoker et al., 2015). The mRNA-seq data have been deposited in the NCBI GEO database (accession number GSE68746).

Indexed as

CancerCD24MammaryMRNA-seqMvt1 cells

Identifiers

PMID26484297
PMCPMC4583690
OpenAlexW1810259636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.